Ureter Cancer Clinical Trials

7 recruiting

Ureter Cancer Trials at a Glance

9 actively recruiting trials for ureter cancer are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Seoul, Beijing, and Rochester. Lead sponsors running ureter cancer studies include Mayo Clinic, Peking University First Hospital, and Yonsei University.

Browse ureter cancer trials by phase

Treatments under study

About Ureter Cancer Clinical Trials

Looking for clinical trials for Ureter Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ureter Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ureter Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Metastatic Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Metastatic Renal Pelvis and Ureter Urothelial Carcinoma+4 more
Mayo Clinic75 enrolled1 locationNCT06764095
Recruiting
Phase 3

Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery

Ureter CancerRenal CancerOther Specified Disorders of Kidney and Ureter+5 more
Hans Bahlmann220 enrolled3 locationsNCT06349668
Recruiting

Integrated Cancer Repository for Cancer Research

Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled45 locationsNCT02012699
Recruiting
Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Stage IV Bladder Cancer AJCC v7Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial Carcinoma+3 more
Mayo Clinic70 enrolled1 locationNCT07087860
Recruiting

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

Urothelial CarcinomaRenal Cell CarcinomaBladder Cancer+2 more
Fox Chase Cancer Center16 enrolled1 locationNCT03291028
Recruiting

Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

Ureter CancerAdvanced Urothelial CarcinomaRenal Pelvic Carcinoma
Peking University First Hospital60 enrolled2 locationsNCT06598761
Recruiting
Not Applicable

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

Oligometastatic DiseaseUreter CancerRenal Pelvic Carcinoma
Peking University First Hospital102 enrolled2 locationsNCT06652022
Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Prostate CancerBladder CancerRenal Cell Cancer+2 more
Yonsei University3,000 enrolled1 locationNCT04625556
Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

Prostate CancerBladder CancerRenal Cell Cancer+1 more
Yonsei University3,000 enrolled1 locationNCT04197414